BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fuhrmann V, Weber T, Roedl K, Motaabbed J, Tariparast A, Jarczak D, de Garibay APR, Kluwe J, Boenisch O, Herkner H, Kellum JA, Kluge S. Advanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure. Ann Intensive Care 2020;10:96. [PMID: 32676849 DOI: 10.1186/s13613-020-00714-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Yan F, Yuan L, Yang F, Wu G, Jiang X. Emerging roles of fibroblast growth factor 21 in critical disease. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1053997] [Reference Citation Analysis]
2 Saliba F, Bañares R, Larsen FS, Wilmer A, Parés A, Mitzner S, Stange J, Fuhrmann V, Gilg S, Hassanein T, Samuel D, Torner J, Jaber S. Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts. Intensive Care Med 2022;48:1352-67. [PMID: 36066598 DOI: 10.1007/s00134-022-06802-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Acharya M, Berger R, Popov AF. The role of the ADVanced Organ Support (ADVOS) system in critically ill patients with multiple organ failure. Artif Organs 2022. [PMID: 35128695 DOI: 10.1111/aor.14188] [Reference Citation Analysis]
4 Tampe D, Korsten P, Bremer SCB, Winkler MS, Tampe B. Kinetics of Bilirubin and Ammonia Elimination during Hemadsorption Therapy in Secondary Sclerosing Cholangitis Following ECMO Therapy and Severe COVID-19. Biomedicines 2021;9:1841. [PMID: 34944657 DOI: 10.3390/biomedicines9121841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 König C, Kluge S, Fuhrmann V, Jarczak D. Pharmacokinetics of meropenem during advanced organ support (ADVOS®) and continuous renal replacement therapy. Int J Artif Organs 2021;:3913988211021101. [PMID: 34144656 DOI: 10.1177/03913988211021101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Scharf C, Liebchen U, Paal M, Becker-Pennrich A, Irlbeck M, Zoller M, Schroeder I. Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study. Sci Rep 2021;11:10190. [PMID: 33986443 DOI: 10.1038/s41598-021-89712-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
7 Kaps L, Ahlbrand CJ, Gadban R, Nagel M, Labenz C, Klimpke P, Holtz S, Boedecker S, Michel M, Kremer WM, Hilscher M, Galle PR, Kraus D, Schattenberg JM, Weinmann-Menke J. Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. PLoS One 2021;16:e0249342. [PMID: 33793644 DOI: 10.1371/journal.pone.0249342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fuhrmann V, Perez Ruiz de Garibay A, Faltlhauser A, Tyczynski B, Jarczak D, Lutz J, Weinmann-Menke J, Kribben A, Kluge S. Registry on extracorporeal multiple organ support with the advanced organ support (ADVOS) system: 2-year interim analysis. Medicine (Baltimore) 2021;100:e24653. [PMID: 33607801 DOI: 10.1097/MD.0000000000024653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]